Generic placeholder image

Inflammation & Allergy - Drug Targets (Discontinued)


ISSN (Print): 1871-5281
ISSN (Online): 2212-4055

Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules

Author(s): Gianfranco Calogiuri, Eustachio Nettis, Elisabetta Di Leo, Caterina Foti, Antonio Ferrannini and Lavjay Butani

Volume 12, Issue 1, 2013

Page: [19 - 28] Pages: 10

DOI: 10.2174/1871528111312010004

Price: $65


Allopurinol, an analog of hypoxanthine has been worldwide used for the treatment of hyperuricemia and gout for over 40 years. Unfortunately some patients assuming this medication have developed hypersensitivity reactions ranging from mild cutaneous eruption to more severe clinical manifestations such as allopurinol hypersensitivity syndrome or Steven-Johnson syndrome and lethal toxic epidermal necrolysis. Various strategies of slow desensitization have been elaborated to reintroduce allopurinol in a part of these patients, mainly patients affected by mild skin reactions as fixed drug eruption or exanthema. However, several new uricosuric therapies have been recently introduced. Actually drugs as recombinant urate oxidase and febuxostat are under post-marketing surveillance to control potential adverse effects related to their immunogenicity even.

Keywords: Allopurinol, anakinra, desensitization, febuxostat, hypersensitivity, rasburicase, hypoxanthine, gout, TNF-alpha, hyperuricemia

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy